DUBLIN–(BUSINESS WIRE)–The “Genomics
Market Size, Share & Trends Analysis Report By Deliverables, By
Application & Technology (Functional Genomics, Epigenomics), By End Use
(Pharma & Biotech Companies), And Segment Forecasts, 2019 – 2025”
report has been added to ResearchAndMarkets.com’s offering.
The global genomics market size is expected to reach USD 27.6 billion by
2025. The market is projected to expand at a CAGR of 9.1% over the
forecast period.
The past decades have witnessed significant changes in disease
management processes due to simultaneous advancements in genomics and
personalized medicine. There has been a gradual growth in the usage of
genomic studies in clinical practices, which is reflected by the rising
trend of targeted therapies.
Results from genomic studies enable a better understanding of diseases
and the underlying mechanisms for researchers, physicians, and patients.
This facilitates evidence-based decision-making, and hence, helps
improve personalized treatment regime. In addition, technological
advancements in data analysis tools have motivated healthcare community
to create precision-based therapies from surplus, available DNA data.
One of the most important factors, which are likely to have a
significant impact on the market, is that how much and to what extent
the medical community will make the use of available genomic information
in personalized medicine. Furthermore, plummeting cost of sequencing has
enabled the whole genome sequencing at very less price. Scientists are
combining the sequencing generated data with diagnostics, which has
proven its effectiveness in enhancing personalized treatment landscape.
The companies are involved in strategic alliances with global, as well
as local, entities to boost their revenue generation and enhance their
share in the market. For instance, in March 2017, Foundation Medicine
collaborated with Bristol-Myers Squibb Company. This enabled
Bristol-Myers Squibb to deploy Foundation Medicine’s molecular
information solutions and comprehensive genomic profiling for
identification of predictive biomarkers, such as Microsatellite
Instability (MSI) and Tumor Mutational Burden (TMB), to accelerate its
immunotherapy clinical trials.
Further key findings from the study suggest:
-
Growing interest of pharma and biotech companies in genomics is
expected to drive the genomics market in coming years -
NGS-based services held a major share of the market due to its rapid
adoption in whole genome sequencing and application of sequence
databases for disease screening and prognosis -
The demand for these services would remain strong due to growing
customer base from academic and research centers to CROs and biotech
and pharma companies -
Use of predictive biomarkers for diagnosis and monitoring takes cancer
eradication a step further -
Moreover, various organizations and programs are actively
participating in the development of novel biomarkers for cancer
diagnosis -
With the rising health consciousness Direct-To-Consumer (DTC)
laboratory testing is increasingly being employed. Such genetic tests
enable consumers to access information about their genetics without
having to visit healthcare professionals -
Asia Pacific is the potential regional market for genomics. It is
anticipated to expand at the highest CAGR of 11.2% -
Major companies in the market include Beijing Genomics Institute
(BGI); Agilent Technologies; Thermo Fisher Scientific, Inc.; Bio-Rad
Laboratories, Inc.; Foundation Medicine, Inc.; 23andMe, Inc.; Danaher,
Illumina, Inc.; Pacific Biosciences; Oxford Nanopore Technologies; F.
Hoffmann-La Roche Ltd.; and Myriad Genetics, Inc
Key Topics Covered
Chapter 1 Research Methodology
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.4 Information analysis
1.5 Market formulation & data visualization
1.6 Data validation & publishing
Chapter 2 Executive Summary
2.1 Genomics Market Outlook, 2014 – 2025
Chapter 3 Industry Outlook
3.1 Penetration & Growth Prospects Mapping
3.2 Trend analysis
3.3 Genomics – Market Dynamics
3.4 Opportunity Analysis
3.5 Industry Analysis – Porter’s
3.6 Regulatory landscape: Genomics – SWOT by PEST Analysis
3.7 Company market share analysis
3.8 Competitive landscape
Chapter 4 Genomics Market Categorization: Deliverables Outlook
4.1 Genomics Market Share By Deliverables Outlook, 2014 To 2025
4.2 Products Market, 2014 to 2025
4.3 Services Market, 2014 to 2025
Chapter 5 Genomics Market Categorization: Technology – Application
Outlook
5.1 Genomics Market Share By Technology – Application Outlook, 2014 To
2025
5.2 Functional Genomics, 2014 to 2025
5.3 Epigenetics, 2014 to 2025
5.4 Pathway Analysis, 2014 to 2025
5.5 Biomarker Discovery, 2014 to 2025
5.6 Others, 2014 to 2025
Chapter 6 Genomics Market Categorization: End-use Outlook
6.1 Genomics Market Share by End-Use, 2014 to 2025
6.2 Clinical & Research Laboratories, 2014 to 2025
6.3 Academic and Government Institutes, 2014 to 2025
6.4 Hospitals and Clinics, 2014 to 2025
6.5 Pharmaceutical and Biotechnology Companies, 2014 to 2025
6.6 Other End Users, 2014 to 2025
Chapter 7 Genomics Market Categorization: Regional Outlook
7.1 Genomics Market Share By Region, 2014 to 2025
7.2 North America
7.3 Europe
7.4 Asia Pacific
7.5 Latin America
7.6 MEA
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Agilent Technologies
- BGI
- Bio-Rad Laboratories Inc.
- Danaher
- F. Hoffmann-La Roche Ltd.
- GE Healthcare
- Illumina Inc.
- Oxford Nanopore Technologies
- Pacific Biosciences of California Inc.
- QIAGEN
- Quest Diagnostics Incorporated
- Foundation Medicine Inc.
- Myriad Genetics Inc.
- Eppendorf AG
- Eurofins Scientific
- Color Genomics Inc.
- 23andMe Inc.
For more information about this report visit https://www.researchandmarkets.com/r/vvwy5b
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Genomics